DIAdvisor

The DIAdvisor is a large scale- integrating project (IP) aiming at development of a prediction based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

The DIAdvisor does not depend on specific sensor technologies and technologies like standard strip sensing, minimally invasive continuous glucose sensors and non-invasive methods.

For safety reason, the DIAdvisor system will be able to self-assess the confidence of its proposed decisions. For safety reasons as well as for the sake of therapy improvements the system connects and provides information and trends to the Health Care Provider.

Glucose prediction is difficult and requires advanced science. This can be achieved only by a well-balanced group of eminent experts including academics, clinicians, user representatives and leading companies. This includes physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding.

The expected impact of DIAdvisor will be improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs. Moreover, the project will constitute a valuable opportunity for European companies to build up a special know-how leading products that profoundly and positively impacts the lives of millions with other indications than diabetes.

For further information, please visit:
http://www.diadvisor.eu/

Project co-ordinator:
Novo Nordisk A/S (Denmark)

Partners:

  • Novo Nordisk A/S (Denmark),
  • Johannes Kepler Universität Linz (Austria),
  • Lunds Universitet (Sweden),
  • Universita Degli Studi di Padova (Italy),
  • Centre Hospitalier Regional Universitaire de Montpellier (France),
  • Toumaz Technology Ltd (UK),
  • Sensor Technology and Devices Ltd (UK),
  • Ondalys SARL (France),
  • Romsoft SRL (Romania),
  • Institut Klinicke a Experimentalni Mediciny (Czech Republic),
  • RICAM, Österreichische Akademie der Wissenschaften (Austria),
  • Rambøll Danmark A/S (Denmark),
  • Federation Internationale du Diabete Region Europe (Belgium)

Timetable: from 03/2008 – to 02/2012

Total cost: € 9.284.061

EC funding: € 7.099.992

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...